Effects of Kudiezi Injection on Serum Inflammatory Biomarkers in Patients with Acute Cerebral Infarction

Abstract EN

Background.

Kudiezi injection is a traditional Chinese medicine for acute cerebral infarction, but the exact mechanisms are poorly understood.

Objective.

To investigate the mechanisms of Kudiezi injection on the inflammatory response in the treatment of acute cerebral infarction.

Methods.

This was a prospective study of patients with acute cerebral infarction within 48 h of onset and treated between July 2012 and July 2016 at three hospitals in China.

The patients were randomized to routine treatments (control group) versus routine treatments and Kudiezi injection (Kudiezi group).

The National Institutes of Health Stroke Score was assessed on days 1, 3, 5, 7, and 14.

The patients were tested for serum levels of pro- and anti-inflammatory cytokines (S100 calcium-binding protein B, neuron-specific enolase, interleukin-6, interleukin-10, interleukin-18, and matrix metaloproteinase-9; by enzyme-linked immunosorbent assay) immediately after admission and on days 3, 5, and 14.

Results.

Stroke scores were improved in both groups from days 1 to 14.

On days 5 and 7, stroke scores in the Kudiezi group were lower than in the control group (P<0.05).

Compared with controls, the Kudiezi group had lower serum S100 calcium-binding protein B on day 14; higher interleukin-6 and interleukin-10 on day 3; lower interleukin-6 and interleukin-18 on day 5; and lower interleukin-18 and matrix metaloproteinase-9 on day 14.

Conclusion.

Kudiezi injection could lead to early reduction of interleukin-6, interleukin-18, matrix metaloproteinase-9, neuron-specific enolase, and S100 calcium-binding protein B levels and increases of interleukin-10 levels in patients with acute ischemic stroke.

This trial is registered with ClinicalTrials.gov NCT01636154.